查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1916895

依药物类别、给药途径、剂型、通路和最终用户分類的痛风治疗市场－2026-2032年全球预测

Gout Medications Market by Drug Class, Route Of Administration, Dosage Form, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，痛风治疗市场价值将达到 29.8 亿美元，到 2026 年将成长至 31.5 亿美元，到 2032 年将达到 45.6 亿美元，复合年增长率为 6.23%。

关键市场统计数据
基准年 2025 29.8亿美元
预计年份：2026年 31.5亿美元
预测年份 2032 45.6亿美元
复合年增长率 (%) 6.23%

对于当今的相关人员，这是对当前临床、商业性和监管环境的精闢介绍，这些环境正在重塑全球痛风药物格局。

痛风仍然是一个临床意义重大且商业性前景广阔的治疗领域，其发展受到不断演变的治疗标准、新兴的生物製药製剂和小分子药物以及不断变化的患者就医模式的影响。临床医生仍在努力平衡急性症状管理和长期降尿酸策略，而支付者和采购团队则要求提供证据，证明干预措施能够带来可衡量的疗效和成本效益。药物研发和医疗服务领域的创新融合，正在引入新的治疗选择，同时也增加了确定最佳治疗方案的复杂性。

变革性的转变正在改变患者照护路径、创新管道和支付方考量，重新定义全球痛风治疗的模式。

痛风治疗领域正经历着变革性的转变，影响着临床实务、商业化和供应链的韧性。生物製药和重组尿酸降解酶製剂的进步为难治性高尿酸血症提供了强有力的治疗选择，促使临床医生重新评估强化治疗方案和治疗顺序。同时，小分子化学和製剂技术的进步提高了传统药物的安全性和耐受性，从而提高了患者的依从性并扩大了门诊管理范围。这些药理学上的进步与数位医疗的普及应用相融合，包括远端医疗、远距监测和患者支援平台，从而扩大了专科医疗服务的覆盖范围，并实现了更持续的追踪。

对2025年美国关税对痛风药物供应链、采购和定价的影响进行全面分析

美国2025年实施的关税调整对痛风药物生态系统产生了多方面的影响，波及成本、采购决策和供应链结构。某些药品原料和成品的关税上调增加了依赖国际采购活性药物成分（API）的药物的到岸成本。随着采购部门的应对，各机构开始实现供应商多元化，并加速其他API供应商的资格认证，以降低单一来源采购的风险。这些变化迫使企业重新谈判合约，并将总到岸成本的考量置于药品清单和采购决策的首要位置。

关键细分观点揭示了不同药物类别、给药途径和最终用户的临床效用、采购行为和分销动态差异。

从细分观点，不同药物类别、给药途径、分销管道、剂型和终端用户环境之间存在显着的临床、商业性和分销动态差异。在各类药物中，秋水仙碱等传统药物与非类固醇消炎剂（NSAIDs）并存，后者包括Ibuprofen、Indometacin和萘普生等成熟药物。其他类别包括重组尿酸酶製剂，如培格洛汀酶和拉司布林酶；促尿酸排泄药，如苯溴马隆、雷西纳德和丙磺舒；以及黄嘌呤氧化酶抑制剂，包括Allopurinol、非布司他和托吡司他等代表药物。每类药物都有其独特的疗效和安全性权衡，这影响着它们在治疗流程中的定位。重组尿酸酶製剂通常用于难治性病例，而黄嘌呤氧化酶抑制剂则是慢性降尿酸策略的基础。

对美洲、欧洲、中东和非洲以及亚太市场的需求驱动因素、监管影响和准入挑战进行区域比较分析

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的药物可近性、应用和商业策略有显着影响。在美洲，市场趋势往往受到私人保险、公共支付方和综合医疗服务体系相互作用的影响，从而形成多元化的报销环境，这种环境奖励那些具有明确临床差异化和强有力的药物经济学证据的药物。製造商通常会投资于病患支援服务和疗效记录，以确保药物能够被纳入药品目录，并在慢性病照护机构中维持较高的用药依从性。

企业定位和竞争策略塑造了痛风治疗领域创新者和成熟製造商之间的产品组合、联盟和研发投资。

在痛风治疗领域，各公司之间的竞争融合了现有产品组合管理、精准创新和策略联盟。现有製药企业拥有广泛的产品组合、深厚的经销网络，并在复杂的医保谈判方面经验丰富，这使它们能够透过产品生命週期管理和製剂改进来巩固市场地位。同时，生物技术和专科药物研发企业正在推广重组尿酸降解酶疗法和新型分子疗法，以满足难治性患者群体未被满足的医疗需求，并透过临床差异化赢得专科医生的处方。

为行业领导者提供切实可行的策略建议，以确保供应链韧性、优化产品系列併调整商业模式以适应不断变化的相关人员需求。

在痛风治疗领域，产业领导者可以采取多项切实可行的措施来巩固市场地位、保障利润并改善病患疗效。首先，应优先考虑供应链韧性，具体措施包括：实现原料药(API) 和成品药供应商多元化、建立区域性生产体系，以及透过先进的库存和物流分析提高供应链透明度。这些措施有助于降低关税波动和地缘政治动盪带来的风险，同时提高对需求波动的应对力。其次，应优化分销和商业资源配置，确定能够满足门诊、住院和居家管理需求的剂型和给药途径，并制定与临床路径相符的产品组合策略。

报告的基本调查方法严谨可靠，结合了数据三角测量、同行检验、定性和定量技术，以确保得出公正可靠的结论。

本报告的研究采用了多种方法，对来自各种高品质资讯来源的证据进行三角验证，并透过专家意见检验研究结果。主要定性研究包括对临床医生、处方集决策者、采购专业人员和供应链经理进行结构化访谈，以收集有关治疗选择决定因素、给药偏好和运营限制的第一手资讯。次要分析综合了已发布的监管文件、同行评审的临床文献和试验註册信息，以记录关键治疗领域的临床和安全性现状。来自物流和分销案例研究的营运数据用于评估供应链的脆弱性和缓解措施。

对痛风治疗生态系统进行全面综合分析，提炼其对临床实务、供应链策略和商业性决策的启示

总之，痛风治疗领域治疗方法，既有成熟治疗方法，也有新兴疗法，同时也面临监管压力和营运限制，这给价值链上的所有相关人员带来了风险和机会。临床创新（特别是重组尿酸酶和改良的黄嘌呤氧化酶抑制剂）正在拓展治疗选择，而病人参与的提高和数位医疗基础设施的改善正在改变医疗服务模式。同时，政策变革和供应链中断凸显了韧性、透明的成本模型和策略采购规划的重要性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依药物类别分類的痛风治疗市场

  • 秋水仙碱
  • 非类固醇消炎剂
    • Ibuprofen
    • Indometacin
    • 萘普生
  • 重组尿酸酶
    • 佩格洛蒂卡泽
    • 拉斯布里卡泽
  • 尿酸排泄促进剂
    • 苯溴马隆
    • 莱西努拉德
    • 丙磺舒
  • 黄嘌呤氧化酶抑制剂
    • Allopurinol
    • 非布司他
    • 托吡罗昔康

9. 痛风治疗市场（依给药途径划分）

  • 静脉注射
  • 口服
  • 皮下注射

第十章 依剂型分類的痛风治疗市场

  • 胶囊
  • 注射液
  • 口服液
  • 药片

第十一章 痛风治疗市场依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 痛风治疗市场（依最终用户划分）

  • 门诊手术中心
  • 诊所
  • 居家医疗
  • 医院

第十三章 各地区痛风治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 痛风治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国痛风治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国痛风治疗市场

第十七章 中国痛风治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Cipla Limited
  • Hikma Pharmaceuticals PLC
  • Horizon Therapeutics plc
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
  • Torrent Pharmaceuticals Limited
  • Viatris Inc.
Product Code: MRR-AE420CB153DA

The Gout Medications Market was valued at USD 2.98 billion in 2025 and is projected to grow to USD 3.15 billion in 2026, with a CAGR of 6.23%, reaching USD 4.56 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.98 billion
Estimated Year [2026] USD 3.15 billion
Forecast Year [2032] USD 4.56 billion
CAGR (%) 6.23%

An incisive introduction to the current clinical, commercial, and regulatory dynamics reshaping the global gout therapeutics landscape for modern stakeholders

Gout remains a clinically significant and commercially dynamic therapeutic area, shaped by evolving standards of care, emerging biologic and small-molecule options, and changing patterns of patient access. Clinicians continue to balance acute symptom management with long-term urate-lowering strategies, while payers and procurement teams demand evidence that interventions deliver measurable outcomes and cost-efficiencies. Converging innovations in drug development and healthcare delivery have introduced new therapeutic choices and heightened the complexity of adjudicating optimal treatment pathways.

Against this backdrop, stakeholders require a concise yet rigorous introduction that frames current treatment modalities, regulatory environments, and the operational pressures affecting supply and distribution. This introduction contextualizes the interplay between clinical efficacy, safety profiles, route of administration preferences, and the logistical realities of getting therapies from manufacturer to patient. It also outlines the competitive landscape in which established small-molecule treatments coexist with recombinant biologic agents, and in which differentiation is increasingly driven by real-world evidence and patient-centric service bundles.

The reader should emerge from this section with a clear understanding of the foundational dynamics that inform subsequent analysis: the therapeutic categories in play, the key decision points for payers and providers, and the structural drivers of change that will influence strategic choices across the value chain.

Transformative shifts altering patient care pathways, innovation pipelines, and payer considerations that are redefining gout treatment paradigms worldwide

The gout therapeutics landscape is undergoing transformative shifts that affect clinical practice, commercialization, and supply chain resilience. Advances in biologic therapies and recombinant uricase agents have introduced potent options for refractory hyperuricemia, prompting clinicians to reassess escalation pathways and therapeutic sequencing. Simultaneously, improvements in small-molecule chemistry and formulation have refined safety and tolerability profiles for longstanding classes, enabling better adherence and broader outpatient management. These pharmacological advances intersect with digital health adoption, where telemedicine, remote monitoring, and patient support platforms are extending the reach of specialist care and enabling more consistent follow-up.

Concurrently, payer expectations and procurement strategies are evolving toward value-based arrangements that emphasize measurable clinical outcomes and total cost of care. Health systems increasingly demand real-world evidence to justify formulary placement, and this is accelerating investments in observational studies and outcomes registries. At the same time, supply chain considerations have gained prominence: manufacturers and distributors are prioritizing resilience through supplier diversification, regional manufacturing capacity, and strategic inventory management. Regulatory pathways have adapted to reflect these shifts, offering expedited mechanisms for high-need therapeutics and clearer guidance for biosimilars and interchangeability, which in turn alter competitive landscapes. Taken together, these changes are reshaping how therapies are developed, positioned, and delivered, creating both challenges and opportunities for stakeholders seeking sustainable differentiation.

Comprehensive analysis of how recent United States tariff policies enacted in 2025 are cascading through supply chains, procurement, and pricing for gout therapeutics

The tariff changes implemented in the United States in 2025 have exerted a multifaceted influence across the gout medication ecosystem, impacting costs, sourcing decisions, and supply chain configurations. Increased duties on select pharmaceutical inputs and finished products have elevated landed costs for medications that rely on internationally sourced active pharmaceutical ingredients. As procurement teams reacted, organizations initiated supplier diversification and accelerated qualification of alternate API suppliers to mitigate single-source exposure. These shifts forced contract renegotiations and brought total landed cost considerations to the foreground of formulary and procurement deliberations.

In response, some manufacturers examined the feasibility of regionalizing production to reduce tariff-induced volatility, while distributors reassessed inventory strategies to balance availability against capital tied up in safety stock. The tariff environment also influenced pricing dynamics in negotiations with payers and integrated delivery networks, where increased list prices faced heightened scrutiny tied to value demonstration. Moreover, procurement cycles lengthened as buyers sought to understand the long-term implications of policy changes and to incorporate contingency clauses into supplier agreements. Patient access programs and support services became more prominent as manufacturers looked to buffer end users from near-term cost pressures.

Looking ahead, the cumulative effect of these policies has been to elevate the strategic importance of flexible manufacturing, closer supplier relationships, and transparent cost modeling. Stakeholders that prioritize supply chain visibility and proactive sourcing stand better positioned to navigate tariff-driven disruptions while maintaining continuity of care for patients dependent on gout therapeutics.

Key segmentation perspectives that reveal differing clinical utility, procurement behaviors, and distribution dynamics across drug classes, administration routes and end users

A segmentation-focused lens reveals differentiated clinical, commercial, and distribution dynamics across drug classes, administration routes, distribution channels, dosage forms, and end-user settings. Within drug class, traditional agents such as colchicine coexist with Nonsteroidal Anti-Inflammatory Drugs that include well-established options like ibuprofen, indomethacin, and naproxen; recombinant uricase modalities exemplified by pegloticase and rasburicase; uricosuric agents such as benzbromarone, lesinurad, and probenecid; and xanthine oxidase inhibitors with representatives including allopurinol, febuxostat, and topiroxostat. Each class carries unique efficacy and safety trade-offs that influence where it fits in treatment algorithms, with recombinant uricase often reserved for refractory cases while xanthine oxidase inhibitors underpin chronic urate-lowering strategies.

Route of administration considerations-intravenous, oral, and subcutaneous-shape both clinical workflow and patient preference, influencing where therapies are delivered and which stakeholders manage administration. Distribution channel behaviors vary by channel type: hospital pharmacies tend to prioritize on-formulary, inpatient-ready therapies with established tender relationships, online pharmacies focus on convenience and chronic adherence, and retail pharmacies balance front-end accessibility with payer constraints. Dosage form differences across capsules, injectable solutions, oral solutions, and tablets also affect adherence, shelf life, and storage requirements, feeding directly into distribution and inventory planning.

End-user distinctions across ambulatory surgical centers, clinics, home care, and hospitals determine setting-specific demand patterns, reimbursement pathways, and service expectations. For example, therapies requiring intravenous administration concentrate demand within hospital and clinic settings, whereas oral formulations support broader deployment across home care and retail channels. Understanding these segmentation interdependencies is essential for tailoring clinical positioning, commercial outreach, and supply chain strategies to the realities of different stakeholder groups.

Regional intelligence that contrasts demand drivers, regulatory influences, and access challenges across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Regional dynamics exert a powerful influence on access, adoption, and commercial strategy across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, market behavior is frequently shaped by an interplay of private insurance, public payers, and integrated delivery systems, creating heterogeneous reimbursement environments that reward clear clinical differentiation and robust pharmacoeconomic evidence. Manufacturers often invest in patient support services and outcomes documentation to secure favorable formulary status and to sustain adherence in chronic treatment settings.

In Europe, Middle East & Africa, regulatory and pricing frameworks emphasize health technology assessment and cost-effectiveness, encouraging manufacturers to engage early with payers and to demonstrate comparative benefits. Tender processes and national procurement authorities often drive volume-based purchasing decisions, while regional variance in access can create pockets of both advanced biologic uptake and high reliance on generics. Across Asia-Pacific, rapid adoption of innovative therapies in certain markets coexists with cost-sensitive procurement in others, incentivizing manufacturers to calibrate market entry strategies by country and to build local partnerships or manufacturing presence to enhance competitiveness and compliance.

Across all regions, differences in supply chain infrastructure, regulatory timelines, and clinical practice patterns require nuanced approaches to commercialization and distribution. Manufacturers that adapt their go-to-market models to regional payer structures, invest in local evidence generation, and cultivate strategic partnerships are better positioned to navigate the varied landscape and to expand patient access while managing commercial risk.

Corporate positioning and competitive maneuvers shaping portfolios, partnerships, and R&D investments among innovators and established manufacturers in gout therapeutics

Competitive dynamics among companies active in the gout therapeutics space reflect a blend of legacy portfolio management, targeted innovation, and strategic partnerships. Established pharmaceutical manufacturers maintain broad portfolios with deep distribution networks and experience navigating complex payer negotiations, enabling them to defend market positions through lifecycle management and incremental formulation improvements. At the same time, biotechnology firms and specialty developers are advancing recombinant uricase therapies and novel molecular approaches that address unmet needs in refractory patient populations, using clinical differentiation to gain traction among specialist prescribers.

Contract manufacturing organizations and specialty generics producers play critical roles in ensuring supply continuity, executing on cost-efficient production while complying with global regulatory standards. Distributors and specialty pharmacies focus on patient support and adherence programs that improve real-world outcomes and strengthen manufacturer-payer relationships. Across the ecosystem, strategic behaviors such as licensing deals, co-development agreements, and targeted acquisitions are common as organizations seek capabilities they lack internally-whether that is biologics manufacturing, regional access expertise, or digital patient engagement platforms.

Companies that combine clinical development excellence with operational agility, transparent pricing models, and strong real-world evidence packages tend to secure preferential positioning with payers and providers. Those able to integrate upstream manufacturing flexibility with downstream patient services will likely navigate reimbursement pressures more effectively and sustain long-term relationships with health systems and specialty clinics.

Actionable strategic recommendations enabling industry leaders to secure supply resilience, optimize product portfolios, and align commercial models to evolving stakeholder needs

Industry leaders can take several practical actions to strengthen market position, protect margins, and enhance patient outcomes within the gout therapeutics ecosystem. Prioritize supply chain resilience by diversifying API and finished-dose suppliers, establishing regional manufacturing contingencies, and enhancing visibility through advanced inventory and logistics analytics. These measures reduce exposure to tariff fluctuations and geopolitical disruptions while improving responsiveness to demand shifts. Simultaneously, align portfolio strategy to clinical pathways by identifying which formulations and administration routes match the needs of ambulatory care, hospital settings, and home-based management, thereby optimizing channel-specific distribution and commercial resource allocation.

Engage proactively with payers and health technology assessment bodies to build compelling value dossiers grounded in real-world evidence and comparative effectiveness studies. Invest in patient support programs and adherence tools that demonstrate measurable outcomes, as these services can influence formulary decisions and reduce total cost of care. Consider strategic partnerships with biotech innovators to access recombinant or biologic capabilities, and use licensing or joint-development agreements to expand therapeutic breadth without disproportionate capital investment. Finally, adopt flexible commercial models that include outcomes-based contracting where appropriate, and leverage digital engagement to improve patient education and follow-up. Implementing these steps will strengthen negotiating positions, improve patient retention, and create defensible differentiation in a crowded therapeutic field.

Robust research methodology outlining data triangulation, expert validation, and qualitative and quantitative techniques employed to ensure impartial and reliable insights

The research underpinning this report employed a multi-method approach designed to triangulate evidence from diverse, high-quality sources and to validate findings through expert input. Primary qualitative inquiry included structured interviews with clinicians, formulary decision-makers, procurement specialists, and supply chain leaders to capture firsthand perspectives on therapeutic choice drivers, administration preferences, and operational constraints. Secondary analysis synthesized publicly available regulatory filings, peer-reviewed clinical literature, and trial registries to document the clinical and safety landscape for key therapeutic classes. Operational data from logistics and distribution case studies informed assessments of supply chain vulnerabilities and mitigation strategies.

Analytical methods combined thematic coding of qualitative data with comparative assessment frameworks that evaluated therapeutic differentiation, channel suitability, and regional access factors. Findings were iteratively reviewed with subject matter experts to ensure interpretive accuracy and to surface nuances that raw data alone might obscure. Where possible, real-world evidence and outcomes studies were used to corroborate claims about adherence, tolerability, and setting-of-care impacts. The methodology places emphasis on transparency: assumptions are documented, limitations are acknowledged, and confidence levels are indicated for insights that rely on evolving or incomplete datasets. Ethical standards for research conduct were maintained throughout, with care taken to protect interviewee anonymity and to avoid conflicts of interest in source selection.

Concluding synthesis that distills implications for clinical practice, supply chain strategy, and commercial decision-making in the gout medication ecosystem

In conclusion, the gout therapeutics landscape presents a complex blend of established and emerging treatments, regulatory pressures, and operational constraints that together create both risk and opportunity for stakeholders across the value chain. Clinical innovation-most notably in recombinant uricase and refined xanthine oxidase inhibition-has expanded therapeutic options, while improvements in patient engagement and digital health infrastructure are reshaping delivery models. At the same time, policy shifts and supply chain disruptions underscore the importance of resilience, transparent cost modeling, and strategic sourcing.

For decision-makers, the imperative is to translate these insights into concrete actions: refine portfolio priorities to match setting-specific needs, deepen engagement with payers through robust evidence generation, and shore up supply chains to withstand policy-driven perturbations. Organizations that integrate clinical differentiation with operational agility and patient-centric services will be better positioned to secure favorable formulary placement and to deliver consistent care. The report's synthesis equips leaders with the context and recommendations needed to make informed choices that balance clinical benefit, access, and commercial viability in an evolving market environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gout Medications Market, by Drug Class

  • 8.1. Colchicine
  • 8.2. Nonsteroidal Anti-Inflammatory Drugs
    • 8.2.1. Ibuprofen
    • 8.2.2. Indomethacin
    • 8.2.3. Naproxen
  • 8.3. Recombinant Uricase
    • 8.3.1. Pegloticase
    • 8.3.2. Rasburicase
  • 8.4. Uricosuric Agents
    • 8.4.1. Benzbromarone
    • 8.4.2. Lesinurad
    • 8.4.3. Probenecid
  • 8.5. Xanthine Oxidase Inhibitors
    • 8.5.1. Allopurinol
    • 8.5.2. Febuxostat
    • 8.5.3. Topiroxostat

9. Gout Medications Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Gout Medications Market, by Dosage Form

  • 10.1. Capsules
  • 10.2. Injectable Solutions
  • 10.3. Oral Solutions
  • 10.4. Tablets

11. Gout Medications Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Gout Medications Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Home Care
  • 12.4. Hospitals

13. Gout Medications Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Gout Medications Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Gout Medications Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Gout Medications Market

17. China Gout Medications Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Cipla Limited
  • 18.6. Hikma Pharmaceuticals PLC
  • 18.7. Horizon Therapeutics plc
  • 18.8. Lupin Limited
  • 18.9. Novartis AG
  • 18.10. Pfizer Inc.
  • 18.11. Takeda Pharmaceutical Company Limited
  • 18.12. Teva Pharmaceutical Industries Limited
  • 18.13. Torrent Pharmaceuticals Limited
  • 18.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GOUT MEDICATIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GOUT MEDICATIONS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GOUT MEDICATIONS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GOUT MEDICATIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GOUT MEDICATIONS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GOUT MEDICATIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY COLCHICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY COLCHICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY COLCHICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INDOMETHACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INDOMETHACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INDOMETHACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY PEGLOTICASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY PEGLOTICASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY PEGLOTICASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RASBURICASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RASBURICASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RASBURICASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY BENZBROMARONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY BENZBROMARONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY BENZBROMARONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY LESINURAD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY LESINURAD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY LESINURAD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY PROBENECID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY PROBENECID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY PROBENECID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ALLOPURINOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ALLOPURINOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ALLOPURINOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY FEBUXOSTAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY FEBUXOSTAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY TOPIROXOSTAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY TOPIROXOSTAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY TOPIROXOSTAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ORAL SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ORAL SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. GCC GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 196. GCC GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 197. GCC GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 198. GCC GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. GCC GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 201. GCC GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. GCC GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. G7 GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 226. G7 GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 227. G7 GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 228. G7 GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. G7 GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 231. G7 GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. G7 GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. NATO GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 236. NATO GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 237. NATO GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. NATO GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 241. NATO GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. NATO GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES GOUT MEDICATIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA GOUT MEDICATIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)